Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts, Mark A Socinski, Paul L Mitchell, Nick Thatcher, Libor Havel, Maciej Krzakowski, Sergiusz Nawrocki, Tudor-Eliade Ciuleanu, Lionel Bosquee, Jose Manuel Trigo, Alexander Spira, Lise Tremblay, Jan Nyman, Rodryg Ramlau, Gun Wickart-Johansson, Peter Ellis, Oleg Gladkov, Jose Rodrigues Pereira, Wilfried Ernst Erich Eberhardt, Christoph Helwig Show all
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2014
This trial was sponsored by Merck KGaA, Darmstadt, Germany. We thank the patients and their families and the investigators and study teams involved. Medical writing assistance was provided by Paola Accalai (International Medical Press, London, UK) and was funded by Merck KGaA.